Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company…
KOMZIFTI (ziftomenib) Added to National Comprehensive Cancer Network (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for R/R NPM1-mutated…
Andor Health’s Agentic AI Platform, ThinkAndor, Receives Frost & Sullivan’s 2025 North American Transformational Innovation Leadership Recognition for Excellence in Acute Care Virtual Health
Recognized for its transformational innovation and customer impact in driving the evolution…
LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE
Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase…
Advanced CAR-T Cell Therapy in a Young Engineer Battling High-Risk Pre-B Acute Lymphoblastic Leukemia
KOLKATA, India, Sept. 25, 2025 /PRNewswire/ -- In a major milestone for…
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial…
